Pathophysiology of hepatic encephalopathy: A new look at GABA from the molecular standpoint

Metabolic Brain Disease

Volumn 19, Issue 3-4, 2004, Pages 331-343

  Ahboucha, Samir ^a   Butterworth, Roger F ^a  

^a Canada   (Canada)

Author keywords

ammonia; benzodiazepines; flumazenil; GABA; Hepatic encephalopathy; neurosteroids

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BRAIN EXTRACT; FLUMAZENIL; NEUROSTEROID;

4 AMINOBUTYRIC ACID UPTAKE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFECT; ELECTROENCEPHALOGRAM; GABAERGIC TRANSMISSION; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; PATHOPHYSIOLOGY;

ANIMALS; BENZODIAZEPINES; BRAIN; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; HEPATIC ENCEPHALOPATHY; HUMANS; RECEPTORS, GABA; STEROIDS; UP-REGULATION;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 5444234245     PISSN: 08857490     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MEBR.0000043979.58915.41     Document Type: Conference Paper

References (54)

1. Ahboucha, S., Desjardins, P., Chatauret, N., Pomier-Layrargues, G., and Butterworth, R.F. (2003). Normal coupling of brain benzodiazepine and neurosteroid modulatory sites on the GABA-A receptor complex in human hepatic encephalopathy. Neurochem. Int. 43:551-556.
2. Ahboucha, S., Pomier-Layrargues, G., and Butterworth, R.F. (2004). Increased brain concentrations of endogenous (non-benzodiazepine) GABA-A receptor ligands in human hepatic encephalopathy. Metab. Brain. Dis. 19:243-253.
3. Albrecht, J. (1998). Roles of neuroactive amino acids in ammonia neurotoxicity. J. Neurosci. Res. 51:133-138.
4. Albrecht, J., and Jones, E.A. (1999). Hepatic encephalopathy: Molecular mechanisms underlying the clinical syndrome. J. Neurol. Sci. 170:138-146.
5. Bansky, G., Meier, P.S., Ziegler, W.H., Walser, H., Schmid, H., and Huber, M. (1985). Reversal of hepatic coma by benzodiazepine antagonists (Rol5-1788). Lancet 1:1324-1325.
6. Baraldi, M., Zeneroli, M.L., Ventura, E., Penne, A., Pinelli, G., Ricci, P., and Santi, M., (1984). Supersensitivity of benzodiazepine receptors in hepatic encephalopathy due to fulminant hepatic failure in the rat: Reversal by a benzodiazepine antagonist. Clin. Sci. 67:167-175.
7. Basile, A.S., Gammal, S.H., Mullen, K.D., Jones, E.A., and Skolnick, P. (1988). Differential responsiveness of cerebellar Purkinje neurons to GABA and benzodiazepine receptor ligands in an animal model of hepatic encephalopathy. J. Neurosci. 8:2414-2421.
8. Basile, A.S., Harrison, P.M., Hughes, R.D., Gu, Z.Q., Pannell, L., McKinney, A., Jones, E.-A., and Williams, R. (1994). Relationship between plasma benzodiazepine receptor ligand concentrations and severity of hepatic encephalopathy. Hepatology 19:112-121.
9. Bassett, M.L., Mullen, K.D., Scholz, B., Fenstermacher, J.D., and Jones, E.A. (1990). Increased brain uptake of gamma-aminobutyric acid in a rabbit model of hepatic encephalopathy. Gastroenterology 98:747-757.
10. Butterworth, R.F., and Giguère, J.F. (1986). Cerebral aminoacids in portal-systemic encephalopathy: Lack of evidence for altered gamma-aminobutyric acid (GABA) function. Metab. Brain Dis. 1:221-228.
11. 3H]muscimol (GABA-A) binding sites and of central benzodiazepine receptors are unchanged in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. Hepatology 8:1084-1088.
12. Butterworth, R.F., Wells, J., and Pomier-Layrargues, G. (1995). Detection of benzodiazepines in hepatic encephalopathy: Reply. Hepatology 21:605.
13. Dodd, P.R., Thomas, G.J., Harper, C.G., and Kril, J.J. (1992). Amino acid neurotransmitter receptor changes in cerebral cortex in alcoholism: Effect of cirrhosis of the liver. J. Neurochem. 59:1506-1515.
14. Grimm, G., Ferenci, P., Katzenschlager, R., Madl, C., Schneeweiss, B., Laggner, A.N., Lenz, K., and Gangl, A., (1988). Improvement of hepatic encephalopathy treated with flumazenil. Lancet 2:1392-1394.
15. Gyr, K., Meier, R., Haussler, J., Bouletreau, P., Fleig, W.E., Gatta, A., Holstege, A., Pomier-Layrargues, G., Schalm, S.W., Groeneweg, M., Scollo-Lavizzari, G., Ventura, E., Zeneroli, M.L., Williams, R., Yoo, Y., and Amrein, R. (1996). Evaluation of the efficacy and safety of flumazenil in the treatment of portal-systemic encephalopathy: A double blind, randomized, placebo controlled multicenter trial. Gut 39:319-324.
16. Hamberger, A., and Nystrom, B. (1984). Extra- and intracellular amino acids in the hippocampus during development of hepatic encephalopathy. Neurochem. Res. 9:1181-1192.
17. A receptor complex. J. Pharmacol. Exp. Ther. 241:346-353.
18. Itzhak, Y., Roig-Cantisano, A., Dombro, R.S., Norenberg, M.D. (1995). Acute liver failure and hyperammonemia increase peripheral-type benzodiazepine receptor binding and pregnenolone synthesis in mouse brain. Brain Res. 705:345-348.
19. Jalan, R., Turjanski, N., Taylor-Robinson, S.D., Koepp, M.J., Richardson, M.P., Wilson, J.A., Bell, J.D., and Brooks, D.J. (2000). Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut 46:546-552.
20. Jones, E.A. (2002). Ammonia, the GABA neurotransmitter system, and hepatic encephalopathy. Metab. Brain Dis. 17:275-281.
21. Jones, E.A., and Basile, A.S. (1997). The involvement of ammonia with the mechanisms that enhance GABA-ergic neurotransmission in hepatic failure. In (V. Felipo and S. Grisolia, eds.), Advances in Cirrhosis, Hyperammonemia, and Hepatic Encephalopathy, Plenum, New York, pp. 75-83.
22. Jones-Davis, D.M., and MacDonald, R.L. (2003). GABA(A) receptor function and pharmacology in epilepsy and status epilepticus. Curr. Opin. Pharmacol. 3:12-18.
23. Klotz, U., and Walker, S. (1989). Flumazenil and hepatic encephalopathy. Lancet 1:155-156.
24. Krogsgaard-Larsen, P. (1992). GABA and glutamate receptors as therapeutic targets in neurodegenerative disorders. Pharmacol. Toxicol. 70:95-104.
25. Lavoie, J., Giguere, J.F., Pomier-Layrargues, G., and Butterworth, R.F. (1987a). Amino acid changes in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy. J. Neurochem. 49:692-697.
26. Lavoie, J., Giguère, J.F., Pomier-Layrargues, G., and Butterworth, R.F. (1987b). Activities of neuronal and astrocytic marker enzymes in autopsied brain tissue from patients with hepatic encephalopathy. Metab. Brain Dis. 2:283-290.
27. Leonard, B.E. (1994). Sleep disorders and anxiety: Biochemical antecedents and pharmacological consequences. J. Psychosom. Res. 38(Suppl. 1):69-87.
28. MacDonald, G.A., Frey, K.A., Agranorf, B.W., Minoshima, S., Koeppe, R.A., Kuhl, D.E., Shulkin, B.L., and Lucey, M.R., (1997). Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy. Hepatology 26:277-282.
29. Maddison, J.E., Dodd, P.R., Morrison, M., Johnston, G.A., and Farrell, G.-C. (1987). Plasma GABA, GABA-like activity and the brain GABA-benzodiazepine receptor complex in rats with chronic hepatic encephalopathy. Hepatology 7:621-628.
30. Majewska, M.D., Demirgoren, S., Spivak, C.E., and London, E.D. (1990). The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor. Brain Res. 526:143-146.
31. Majewska, M.D., and Schwartz, R.D. (1987). Pregnenolone-sulfate: An endogenous antagonist of the gamma-aminobutyric acid receptor complex in brain? Brain Res. 404:355-360.
32. Mans, A.M., Kukulka, K.M., McAvoy, K.J., and Rokosz, N.C. (1992). Regional distribution and kinetics of three sites on the GABA-A receptor: Lack of effect of portacaval shunting. J. Cereb. Blood Flow Metab. 12:334-346.
33. Marczynski, T.J. (1998). GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited. Brain Res. Bull. 45:341-379.
34. Mehta, A.K., and Ticku, M.K. (1999). An update on GABA-A receptors. Brain Res. Rev. 29:196-217.
35. Moroni, F., Riggio, O., Carla, V., Festuccia, V., Ghinelli, F., Marino, I.R., Merli, M., Natali, L., Pedretti, G., Fiaccadori, F., et al. (1987). Hepatic encephalopathy: Lack of changes of gamma-aminobutyric acid content in plasma and cerebrospinal fluid. Hepatology 7:816-820
36. Mullen, K.D., Szauter, K.M., and Kaminsky-Russ, K. (1990). Endogenous benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 336:81-83.
37. Norenberg, M.D., Itzhak, Y., and Bender, A.S. (1997). The peripheral benzodiazepine receptor and neurosteroids in hepatic encephalopathy. Adv. Exp. Med. Biol. 420:95-111.
38. Olasmaa, M., Rothstein, J.D., Guidotti, A., Weber, R.J., Paul, S.M., Spector, S., Zeneroli, M.L., Baraldi, M., and Costa, E. (1990). Endogenous benzodiazepine receptor ligands in human and animal hepatic encephalopathy. J. Neurochem. 55:2015-2033.
39. Paul, S.M., and Purdy, R.H. (1992). Neuroactive steroids. FASEB J. 6:2311-2322.
40. Perney, P., Butterworth, R.F., Mousseau, D.D., Lavoie, J., Fabbro-Peray, P., Blanc, F., and Pomier-Layrargues, G., (1998). Plasma and CSF benzodiazepine receptor ligand concentrations in cirrhotic patients with hepatic encephalopathy: Relationship to severity of encephalopathy and to pharmaceutical benzodiazepine intake. Metab. Brain Dis. 13:201-210.
41. Pomier-Layrargues, G., Giguère, J.F., Lavoie, J., Perney, P., Gagnon, S., D Amour, M., Wells, J., and Butterworth, R.F. (1994). Flumazenil in cirrhotic patients in hepatic coma: A randomized double-blind placebo-controlled crossover trial. Hepatology 19:32-37.
42. Pomier-Layrargues, G., Giguere, J.F., Lavoie, J., Willems, B., and Butterworth, R.F. (1989). Pharmacokinetics of benzodiazepine antagonist Ro 15-1788 in cirrhotic patients with moderate or severe liver dysfunction. Hepatology 10:969-972.
43. Rao, V.L., Audet, R.M., and Butterworth, R.F. (1995). Selective alterations of extracellular brain amino acids in relation to function in experimental portal-systemic encephalopathy: Results of an in vivo microdialysis study. J. Neurochem. 65:1221-1228.
44. Rossle, M., Deckert, J., and Jones, E.A. (1989). Autoradiographic analysis of GABA-benzodiazepine receptors in an animal model of acute hepatic encephalopathy. Hepatology 10:143-147.
45. Roy, S., Pomier-Layrargues, G., Butterworth, R.F., and Huet, P.M. (1988). Hepatic encephalopathy in cirrhotic and portacaval shunted dogs: Lack of changes in brain GABA uptake, brain GABA levels, brain glutamic acid decarboxylase activity and brain postsynaptic GABA receptors. Hepatology 8:845-849.
46. Rupprecht, R. (2003). Neuroactive steroids: Mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28:139-168.
47. Samson, Y., Bernuau, J., Pappata, S., Chavoix, C., Baron, J.C., and Maziere, M.A. (1987). Cerebral uptake of benzodiazepine measured by positron emission tomography in hepatic encephalopathy. N. Engl. J. Med. 316:414-415.
48. Schafer, D.F., Fowler, J.M., Munson, P.J., Thakur, A.K., Waggoner, J.G., and Jones, E.A. (1983). Gamma-aminobutyric acid and benzodiazepine receptors in an animal model of fulminant hepatic failure. J. Lab.Clin. Med. 102:870-880.
49. Scollo-Lavizzari, G., and Steinmann, E. (1985). Reversal of hepatic coma by benzodiazepine antagonist (RO 15-1788). Lancet 1:1324.
50. Squires, R.F., and Saederup, E. (1991). A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: More support for a continuum hypothesis of functional psychosis. Neurochem. Res. 16:1099-1111.
51. Van der Rijt, C.C.D., Schalm, S.W., Meulstree, J., and Stignen, T.H. (1995). Flumazenil therapy for hepatic encephalopathy: A double-blind cross-over study. Gastroenterol. Clin. Dial. 19:572-580.
52. Zeneroli, M.L., Iuliano, E., Racagni, G., and Baraldi, M. (1982). Metabolism and brain uptake of gamma-aminobutyric acid in galactosamine-induced hepatic encephalopathy in rats. J. Neurochem. 38:1219-1222.
53. Zimmermann, C., Ferenci, P., Pifl, C., Yurdaydin, C., Ebner, J., Lassmann, H., Roth, E., and Hortnagl, H. (1989). Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: Characterization of an improved model and study of amino acid-ergic neurotransmission. Hepatology 9:594-601.
54. 13C] nuclear magnetic resonance study. Hepatology 37:420-428.